Similarly, administration of oncolytic adenovirus coexpressing OX40 and CD40 ligands resulted in synergistic activation of OX40 and CD40, induction of tumor-specific CD8+ effector T cells, and improved control of melanoma growth in tumor peptide-vaccinated mice (83). The gene discussed is TNFRSF4; the disease is neoplasm.